StonvexLoading…
StonvexStonvexStonvexCore line items from ENTX's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $42.00K | $181.00K | $0.00 | $134.00K |
Operating Income | $-11.53M | $-9.59M | $-8.89M | $-13.02M |
Net Income | $-11.44M | $-9.54M | $-8.89M | $-13.07M |
EPS (Diluted) | $0.25 | $0.25 | $0.31 | $0.45 |
Total Assets | $15.99M | $9.39M | $11.77M | $13.13M |
Total Liabilities | $2.89M | $1.31M | $1.38M | $1.37M |
Cash & Equivalents | $7.11M | $8.66M | $11.02M | $12.31M |
Free Cash Flow OCF − CapEx | $-7.48M | $-6.82M | $-7.33M | $-12.55M |
Shares Outstanding | 46.18M | 38.84M | 35.48M | 28.81M |